Vident Investment Advisory, LLC Intellia Therapeutics, Inc. Transaction History

Vident Investment Advisory, LLC

  • $0
  • Q3 2023

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
BUY
$34.58 - $46.03 $47,097 - $62,692
1,362 Added 12.05%
12,664 $516,000
Q1 2023

May 15, 2023
BUY
$33.3 - $44.82 $156,376 - $210,474
4,696 Added 71.09%
11,302 $421,000
Q4 2022

Feb 14, 2023
BUY
$33.21 - $62.69 $219,385 - $414,130
6,606 New
6,606 $230,000
Q4 2021

Feb 14, 2022
SELL
$100.76 - $138.36 $164,037 - $225,250
-1,628 Closed
0 $0
Q3 2021

Nov 12, 2021
SELL
$132.37 - $176.78 $118,868 - $158,748
-898 Reduced 35.55%
1,628 $219,000
Q2 2021

Aug 13, 2021
BUY
$60.88 - $161.91 $153,782 - $408,984
2,526 New
2,526 $409,000

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Vident Investment Advisory, LLC Portfolio

Follow Vident Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email